Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy

Tomohiro Matsuo | Yasuyoshi Miyata | Tatsufumi Nakamura | Katsuya Satoh | Hideki Sakai

1Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
2Department of Social Work, Faculty of Human and Social Studies, Nagasaki International University, Sasebo, Japan
3Department of Locomotive Rehabilitation Science, Unit of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Correspondence
Yasuyoshi Miyata, Department of Urology, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Email: int.doc.miya@m3.dion.ne.jp

Funding information
Ministry of Health, Labour and Welfare, Japan, Grant/Award number: 201610100A

Objective: Mirabegron is widely considered as an effective and safe drug for patients with overactive bladder (OAB). However, there is no evidence regarding the efficacy of mirabegron in human T cell lymphotropic virus-1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients with OAB symptoms. The aim of the present study was to clarify the efficacy of mirabegron in HAM/TSP patients with OAB symptoms.

Methods: The present study evaluated the efficacy of mirabegron treatment (50 mg, once daily) in nineteen HAM/TSP patients with OAB symptoms by assessing subjective symptoms using the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) before and 12 weeks after administration. Voided volume (VV), maximum flow rate (Qmax), and post-void residual (PVR) urine volume were evaluated as objective symptoms.

Results: Mirabegron treatment improved OABSS in terms of night-time frequency, urgency, and total score (P < .001). In addition, on the IPSS, mirabegron therapy improved urgency, nocturia, storage symptoms (Questions 2, 4 and 7 on the IPSS), as well as the total score (P < .001). The quality of life (QoL) on the IPSS also improved after treatment (P < .001). However, there were no significant changes in objective symptoms, as measured by VV, Qmax, and PVR, after treatment. One patient (5.3%) complained of dry mouth; because this adverse effect was very mild, the patient did not discontinue mirabegron.

Conclusions: Mirabegron administration improved subjective symptoms in HAM/TSP patients with neurogenic OAB.

KEYWORDS
human T cell lymphotropic virus-1 (HTLV-1)-associated myelopathy, mirabegron, overactive bladder

1 | INTRODUCTION

Human T cell lymphotropic virus-1 (HTLV-1) infects approximately 10–20 million people worldwide. High endemic areas include southern Japan, the Caribbean, Central and South America, the Middle East, Melanesia, and equatorial regions of Africa. HTLV-1, the first human retrovirus to be discovered, causes adult T cell leukemia and HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). In general, HAM/TSP is characterized by slow progression of lower limb sensory disturbances and movement disorder accompanied by neurogenic bladder dysfunction caused by chronic inflammation in the central nervous system (CNS), especially the lower thoracic spinal cord. Both storage and voiding symptoms are very common and are seen even in the very early phase of HAM/TSP. In addition, these symptoms sometimes precede the development of paraparesis by many years. Moreover, lower urinary tract symptoms (LUTS) affect the quality of life (QoL) not only in HAM/TSP patients, but also in HTLV-1-infected individuals. Urinary symptoms occur in up to 100% of patients with...
HAM/TSP, and overactive bladder (OAB) is the main manifestation of HAM/TSP. 7

OAB associated with HAM/TSP is multifarious and affects patients’ QoL. However, there are only a few reports on the efficacy of medications for OAB associated with HAM/TSP. Moreover, HAM/TSP patients with LUTS are not fully satisfied with the efficacy of some medications. 7–10 In some of these patients, the anticholinergic agents prescribed for OAB symptoms caused severe adverse effects, such as constipation and dry mouth, which are autonomic symptoms. In contrast, although methylprednisolone has often been used in HAM/TSP patients with neurogenic bladder, it has limitations in improving LUTS. 10

In addition to these treatments, some advanced medical treatments, such as botulinum toxin type A, have been tried. 7–9 However, these studies did not conclusively prove the efficacy and safety of these treatments because of the small number of patients involved. Therefore, the lack of established curative treatments for LUTS in HAM/TSP patients with OAB symptoms is a critical problem.

Mirabegron is a β3-adrenoreceptor agonist and is approved for the treatment of OAB worldwide. One of the important characteristics of mirabegron is that it causes fewer adverse events, such as constipation or dry mouth, than anticholinergic agents. 11–13 Therefore, mirabegron appears to be advantageous in maintaining QoL in HAM/TSP patients undergoing treatment for OAB. However, there are few data regarding the adverse events associated with mirabegron treatment in these patients. In addition, the efficacy of mirabegron for OAB symptoms associated with HAM/TSP based on subjective parameters and urodynamic assessment has not been fully investigated. Hence, the aim of the present study was to clarify the efficacy and safety of mirabegron in HAM/TSP patients with OAB.

2 | METHODS

The study protocol was approved by the Clinical Studies Review Board of Nagasaki University Hospital and the study was performed in accordance with the principles of the Declaration of Helsinki. Written informed consent was obtained from all patients enrolled in the study.

2.1 | Patients and study design

HAM/TSP patients with OAB symptoms were recruited at the Nagasaki University Hospital. The present study was a prospective single-center open-label study. To be eligible for inclusion in the present study, subjects had to have had HAM/TSP with OAB symptoms (OAB symptom score [OABSS]: urgency ≥2, total score ≥3) for at least 3 months and either not taking any medications for OAB or not responding to anticholinergic agents for at least 3 months (OABSS: urgency ≥2, total score ≥3). All patients had normal micturition desire, and could urinate even if there were some differences in the degree of voided volume. Clean intermittent self-catheterization (CISC) was performed 4 times during the daytime by patients with a large amount of residual urine. The number of CISCs remained unchanged during the study period. Patients received oral mirabegron (Betanis; Astellas Pharma, Tokyo, Japan) 50 mg once daily after breakfast.

Changes in the OABSS and International Prostate Symptom Score (IPSS) 14 were used to assess subjective symptoms, whereas uroflowmetry (UFM) and post-void residual (PVR) urine volume were used as objective measures. "Improvement" was defined when OABSS, IPSS, and IPSS-QoL decreased by 1 point or more for subjective symptoms. Furthermore, patients were divided into 2 groups: an improved group, in which the score for Question 3 on the OABSS (urgency) decreased by ≥1 point, and a failure group. The significance of differences between these 2 groups was evaluated. Motor function was evaluated using Osame’s motor disability score (OMDS). 15

Concomitant therapies, such as immunomodulators, were continued on the condition that the dose was kept constant during the study period. However, patients who had already been prescribed anticholinergic agents for their OAB symptoms stopped taking these drugs for an at least 1-week washout period before initiation of mirabegron treatment. Patients with a history of urological malignancy, pelvic radiotherapy, neurologic disease (except for HAM/TSP), active urinary tract infections, severe hypertension (systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg) not well controlled by medication, renal insufficiency (estimated glomerular filtration rate <30 mL/min/1.73 m²), liver impairment, intending to have a child, or those considered unsuitable for the trial by the treating physicians were excluded from the study. In addition, male patients were excluded, considering the effect of benign prostatic hyperplasia.

2.2 | UFM assessment

The maximum flow rate (Qmax) was measured using the Duet Logic G2 system (Mediwatch UK, Rugby, UK) on free UFM and PVR using transabdominal ultrasound (HI VISION Avius; Hitachi-Aloka Medical, Tokyo, Japan).

2.3 | Statistical analyses

All data are presented as mean ± SD. Wilcoxon’s signed-rank test was used to evaluate changes in subjective symptoms based on the OABSS and IPSS, and in objective symptoms assessed using UFM and PVR. All tests were 2-sided and P < .05 was considered significant. All statistical analyses were performed using JMP 13 (SAS Institute, Cary, NC, USA).

3 | RESULTS

Nineteen women were enrolled in the present study. As indicated in Table 1, the mean (± SD) age of patients was 68.6 ± 8.4 years (range 54–82 years), and the mean duration of illness was 16.1 ± 8.9 years (range 1–38 years). Fifteen patients (78.9%) had taken anticholinergic agents for OAB treatment and 14 (73.7%) had already performed CISC. The OMDS was 5.7 ± 2.9 (range 2–11). All patients were able to complete this clinical trial. No severe adverse events were observed during mirabegron administration.

Table 2 shows changes in the OABSS and IPSS from before to after mirabegron administration. Mirabegron treatment improved the
Data are the mean ± SD (range) or as n (%). CISC, clean intermittent self-catheterization; OMDS, Osame’s motor disability score.

TABLE 1 Patient characteristics

| No. patients | 19 |
|--------------|----|
| Age (y)      | 68.6 ± 8.4 (54–82) |
| Duration of illness (y) | 16.1 ± 8.9 (1–38) |
| OMDS         | 5.7 ± 2.9 (2–11) |
| CISC         | 14 (73.7) |
| Immunomodulator therapy |
| Prednisolone (10 mg) | 4 (21.1) |
| Anticholinergic agents | 15 (78.9) |
| Propiverine hydrochloride | 3 (15.8) |
| Imidafenacin | 2 (10.5) |
| Fesoterodine fumarate | 3 (15.8) |
| Solifenacin succinate | 7 (36.8) |

Unless indicated otherwise, data are given as the mean ± SD (range) or as n (%). CISC, clean intermittent self-catheterization; OMDS, Osame’s motor disability score.

TABLE 2 Changes in the overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) from baseline to 12 weeks after oral administration of mirabegron

|                          | Baseline | Week 12 | P-value |
|--------------------------|----------|---------|---------|
| **OABSS**                |          |         |         |
| Q1 (daytime frequency)   | 1.0 ± 0.7| 0.7 ± 0.7| .63     |
| Q2 (night-time frequency)| 2.5 ± 0.7| 1.6 ± 1.0| <.001   |
| Q3 (urgency)             | 2.9 ± 0.8| 1.4 ± 1.1| <.001   |
| Q4 (urgency incontinence)| 1.5 ± 1.3| 0.6 ± 0.8| .004    |
| Total score              | 7.9 ± 2.2| 4.3 ± 2.8| <.001   |
| **IPSS**                 |          |         |         |
| Q1 (incomplete emptying) | 1.7 ± 1.4| 1.9 ± 0.8| .502    |
| Q2 (frequency)           | 0.9 ± 0.8| 0.6 ± 0.6| .070    |
| Q3 (intermittency)       | 1.1 ± 1.0| 1.0 ± 0.7| 1.000   |
| Q4 (urgency)             | 2.9 ± 0.8| 1.4 ± 1.1| <.001   |
| Q5 (weak stream)         | 1.7 ± 0.9| 1.6 ± 0.7| .555    |
| Q6 (straining)           | 1.1 ± 0.9| 1.1 ± 0.7| 1.000   |
| Q7 (nocturia)            | 2.8 ± 1.1| 1.6 ± 1.0| <.001   |
| Storage symptoms (Q2 + Q4 + Q7) | 6.6 ± 1.6| 3.6 ± 1.7| <.001   |
| Voiding symptoms (Q1 + Q3 + Q5 + Q6) | 5.6 ± 3.1| 5.6 ± 1.3| .889    |
| Total score              | 12.2 ± 3.9| 9.2 ± 2.6| <.001   |
| QoL score                | 4.3 ± 1.1| 3.6 ± 1.0| <.001   |

Data are the mean ± SD. Q, question; QoL, quality of life.

TABLE 3 Changes in urological parameters from baseline to 12 weeks after oral administration of mirabegron

|                        | Baseline | Week 12 | P-value |
|------------------------|----------|---------|---------|
| Bladder capacity (mL)  | 287.9 ± 153.6| 283.0 ± 120.8| .891   |
| Voided volume (mL)     | 130.0 ± 111.8| 109.4 ± 85.0| .120   |
| Qmax (mL/s)            | 8.7 ± 7.7| 7.8 ± 6.6| .598    |
| PVR urine (mL)         | 156.7 ± 107.9| 192.2 ± 134.8| .121   |

Data are the mean ± SD. Qmax, maximum flow rate; PVR, post-void residual.

Changes in objective measures (i.e. bladder capacity, VV, Qmax, and PVR) are given in Table 3. There were no significant changes from baseline to 12 weeks after mirabegron therapy in either bladder capacity (from 287.9 ± 153.6 mL to 283.0 ± 120.8 mL; P = .891), VV (from 130.0 ± 111.8 mL to 90.4 ± 85.0 mL; P = .120), Qmax, or PVR (P = .598 and P = .121, respectively).

Differences in characteristics between the failure and improved groups (based on changes in OABSS Q3) are given in Table 4. Patients in the improved group were younger than those in the failure group. In addition, OMDS in the failure group was higher than in the improved group. However, there were no other significant differences between the 2 groups. The changes in OABSS and IPSS in each group are given in Table 5. There were improvements in total OABSS and IPSS Q7 (nocturia) in both the improved and failure groups. In the case of objective symptoms, UFM assessment showed that PVR in the failure group increased significantly after mirabegron administration (Table 6).

A safety analysis was performed on all patients during the study. One patient (5.3%) complained of dry mouth. However, because this adverse effect was very mild, the patient did not discontinue mirabegron. None of the patients complained of constipation, dry eye, or a decline in cognitive function. In addition, none of the patients with hypertension experienced worsening of their blood pressure levels and pulse rate. Hence, all patients completed this clinical study, including all the scheduled examinations during the study period.

4 | DISCUSSION

The results of the present study indicate that the oral administration of mirabegron improves subjective symptoms, as assessed by OABSS, total IPSS, and IPSS QoL, in HAM/TSP patients with neurogenic OAB. The present study is the first to report on changes in subjective symptoms following mirabegron treatment in HAM/TSP patients with neurogenic OAB. In addition, oral mirabegron therapy was found to be safe for HAM/TSP patients, and the mirabegron therapy did not exacerbate the objective parameters Qmax and PVR.

In patients with HAM/TSP, OAB symptoms such as nocturia and urgency are more frequent than voiding symptoms.16 In addition, it is considered that OAB symptoms are LUTS, and even patients who are HTLV-1 carriers tend to develop OAB symptoms. OAB symptoms are precursors of HAM/TSP because they often precede the clinical manifestation of paraparesis by years.17,18 Furthermore, LUTS have a considerable effect on the QoL of HAM/TSP patients.6,7 Thus, improvement of urinary conditions is important to maintain the QoL.
TABLE 4 Differences in patient characteristics between the failure and improved groups

| Failure group | Improved group | P-value |
|---------------|----------------|---------|
| No. patients (%) | 5 (26.3) | 14 (73.7) | N/A |
| Age (y) | 74.0 ± 5.8 (67–80) | 66.6 ± 8.5 (54–82) | .094 |
| Duration of illness (y) | 18.4 ± 11.5 (9–36) | 12.1 ± 8.6 (1–38) | .217 |
| OMDS | 6.4 ± 2.9 (3–10) | 5.5 ± 3.0 (2–11) | .567 |
| CISC (%) | 5 (100) | 9 (64.3) | .120 |

Unless indicated otherwise, data are given as the mean ± SD (range) or as n (%).

*Mirabegron, which is approved for the treatment of OAB, is a specific agonist acting on β3-adrenoceptors in the human bladder, the stimulation of which leads to active relaxation of the detrusor muscle in the storage phase, which, in turn, increases bladder capacity without exerting an effect on voiding.22 The efficacy and safety of mirabegron have been reported in several randomized trials, for example, the SCORPIO and TAURUS studies.12,23 Both these studies showed improvement in storage symptoms, including urgency incontinence and increased voiding volume. The present study demonstrated that mirabegron improved subjective symptoms (especially nocturia, urgency, and urgency incontinence), which were assessed using the OABSS and IPSS, as well as the QoL of HAM/TSP patients with OAB. However, we did not observe any improvement in subjective symptoms, especially daytime frequency, in the present study. With regard to this point, patients with a large amount of PVR urine had performed CISC at a fixed time, 4 times during the day. The daytime urination frequency was the total number of times of spontaneous voiding and CISC. Patients did not change the number of CISCs performed CISC during the study, the present might explain why the score for daytime frequency did not improve in the present study.

TABLE 5 Differences in overactive bladder symptom score (OABSS) and International Prostate Symptom Score (IPSS) after 12 weeks oral administration of mirabegron between the failure and improved groups

| OABSS | Failure group | Improved group | P-value |
|-------|---------------|----------------|---------|
| Q1 (daytime frequency) | 1.0 ± 0.7 | 0.9 ± 0.8 | .833 |
| Q2 (night-time frequency) | 2.6 ± 0.5 | 1.6 ± 0.5 | .063 |
| Q3 (urgency) | 2.2 ± 0.4 | 2.0 ± 0.6 | .856 |
| Q4 (urgency incontinence) | 1.4 ± 1.1 | 0.6 ± 0.5 | .099 |
| Total score | 7.2 ± 2.6 | 5.4 ± 1.9 | .009 |

| IPSS | Failure group | Improved group | P-value |
|------|---------------|----------------|---------|
| Q1 (incomplete emptying) | 2.0 ± 1.4 | 2.0 ± 0.7 | .983 |
| Q2 (frequency) | 0.6 ± 0.5 | 0.4 ± 0.5 | .765 |
| Q3 (intermittency) | 1.2 ± 0.8 | 1.4 ± 0.9 | .374 |
| Q4 (urgency) | 2.2 ± 0.4 | 2.3 ± 0.4 | .673 |
| Q5 (weak stream) | 1.6 ± 1.1 | 1.2 ± 0.8 | .648 |
| Q6 (straining) | 0.4 ± 0.5 | 1.0 ± 0.7 | .208 |
| Q7 (nocturia) | 3.2 ± 1.3 | 1.6 ± 0.5 | .016 |
| Storage symptoms (Q2 + Q4 + Q7) | 6.0 ± 2.0 | 4.4 ± 0.9 | .056 |
| Voiding symptoms (Q1 + Q3 + Q5 + Q6) | 5.2 ± 3.4 | 5.6 ± 1.1 | .749 |
| Total score | 11.2 ± 3.7 | 10.0 ± 1.9 | .261 |
| QoL score | 4.6 ± 1.3 | 3.6 ± 1.1 | .142 |

Data are the mean ± SD.

*Mirabegron improved subjective symptoms (especially nocturia, urgency, and urgency incontinence), which were assessed using the OABSS and IPSS, as well as the QoL of HAM/TSP patients with OAB. However, we did not observe any improvement in subjective symptoms, especially daytime frequency, in the present study. With regard to this point, patients with a large amount of PVR urine had performed CISC at a fixed time, 4 times during the day. The daytime urination frequency was the total number of times of spontaneous voiding and CISC. Patients did not change the number of CISCs performed CISC during the study, the present might explain why the score for daytime frequency did not improve in the present study.

1. Patients were divided into 2 groups, an improved group (in which the score for Question 3 on the overactive bladder symptom score (urgency) decreased by ≥1 point) and a failure group.
2. Q, question; QoL, quality of life.
Data are the mean ± SD.

Patients were divided into 2 groups (failure and improved groups) on the basis of changes in the OABSS Q3 score. The success rate for mirabegron treatment was 73.7% (14/19). In the improved group, there were significant improvements in the scores for Q2 (nocturia), Q3 (urgency), Q4 (urgency incontinence), and the total score on the OABSS, as well as in scores for Q2 (frequency), Q4 (urgency), Q7 (nocturia), stage symptoms (Q2 + Q4 + Q7), and QoL on the IPSS. The total OABSS, as well as scores for Q7 (nocturia) and storage symptoms on the IPSS improved significantly, even in the failure group. However, we could not determine the effectiveness of mirabegron for objective symptoms, namely bladder capacity, PVR, VV, and Qmax. Although there were no statistically significant changes in VV and PVR in any patient, VV decreased and PVR increased after the study period. In the failure group, all patients performed CISC, and PVR increased significantly after mirabegron treatment. This could be because the present study included 14 patients who had already performed CISC and were expected to have irreversible voiding dysfunction. Moreover, we did not use a frequency volume chart to evaluate the bladder capacity of patients.

In the present study, we paid special attention to adverse events, especially dry mouth and constipation. In previous studies, the rate of adverse events associated with 50 mg mirabegron was similar to that associated with placebo, and was significantly lower than that associated with the antimuscarinic drug tolterodine (4 mg).\textsuperscript{12,23} In addition, several studies have reported that the incidence of adverse events, such as dry mouth and constipation, was similar between patients treated with mirabegron and those treated with placebo.\textsuperscript{11,12,24} However, some studies reported that many HAM/TSP patients suffered from constipation and dry mouth even before treatment.\textsuperscript{25–27} Thus, mirabegron may be more convenient to administer in HAM/TSP patients with OAB than anticholinergic agents. In fact, in the present study, only 1 patient developed mild dry mouth and no patient had constipation. Hence, mirabegron is considered to be a potential treatment option even for HAM/TSP patients who have comorbidities, including autonomic symptoms.

The major limitations of the present study include the relatively small number of patients included and the short observation period. The present study was an open label study and not placebo controlled. In addition, the study population did not include male patients. The patients included in the study did not undergo urodynamic tests, including pressure–flow studies. Moreover, we could demonstrate the efficacy of mirabegron for the objective measures VV and Qmax. Because we did not analyze the placebo effect, we cannot conclude that mirabegron improved subjective symptoms in HAM/TSP patients with OAB. Furthermore, the washout period in the present study is shorter than in other studies using sustained-release and extended-release formulations, such as solifenacin succinate and fesoterodine fumarate.\textsuperscript{28,29} However, the present study has demonstrated, for the first time, that oral mirabegron therapy improved subjective symptoms, as measured by the IPSS and OABSS, in HAM/TSP patients with OAB. The present study is the first to investigate the efficacy of medications used for the treatment of HAM/TSP patients with OAB using established methods. Hence, we believe that despite the study limitations, the results provide important information on the selection of treatment strategies for HAM/TSP patients with OAB. More comprehensive studies with a larger sample size are necessary to confirm the present results.

In conclusion, the results of the present study indicate that the oral administration of mirabegron is effective against subjective symptoms in HAM/TSP patients with OAB. In addition, mirabegron was considered a safe and tolerable therapeutic agent in these patients.

### Acknowledgement

TM and TN are funded by a Health and Labour Sciences Research Grant from the Ministry of Health, Labour and Welfare, Japan (ID: 201610100A).

### Conflict of interest

The authors declare no conflicts of interest.

### ORCID

Yasuyoshi Miyata [https://orcid.org/0000-0001-6272-6657](https://orcid.org/0000-0001-6272-6657)

### REFERENCES

1. De-Thé G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses. 1993;9:381-386.
2. Hollsberg P, Hafler DA. Pathogenesis of diseases induced by human T-lymphotropic virus type I infection. N Engl J Med. 1993;328:1173-1182.
3. Yoshida M. Multiple viral strategies of HTLV-I for dysregulation of cell growth control. Annu Rev Immunol. 2001;19:475-496.
4. Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new entity. Lancet. 1986;8488:1031-1032.

### TABLE 6  Differences between the failure and improved groups\textsuperscript{a} in urological parameters from baseline to 12 weeks after oral administration of mirabegron

|                      | Failure group | Week 12 | P-value | Improved group | Week 12 | P-value |
|----------------------|---------------|---------|---------|----------------|---------|---------|
| **Bladder capacity (mL)** | 337.8 ± 257.3 | 324.6 ± 109.2 | .857 | 270.0 ± 104.9 | 262.2 ± 125.0 | .947 |
| **Voided volume (mL)**   | 127.0 ± 159.4 | 57.0 ± 64.9  | .438 | 131.4 ± 97.4 | 102.9 ± 90.0 | .113 |
| **Qmax (mL/s)**          | 5.0 ± 5.6     | 4.9 ± 5.9  | .870 | 10.0 ± 8.1   | 8.9 ± 6.8  | .472 |
| **PVR urine (mL)**       | 210.8 ± 104.3 | 267.6 ± 133.8 | .015 | 138.7 ± 106.2 | 165.2 ± 129.2 | .910 |

\( ^{a} \) Patients were divided into 2 groups, an improved group (in which the score for Question 3 on the overactive bladder symptom score (urgency) decreased by ≥1 point) and a failure group.
5. Yamano Y, Sato T. Clinical pathophysiology of human T-lymphotropic virus-type 1-associated myelopathy/tropical spastic paraparesis. Front Microbiol. 2012;3:389.

6. Castro NM, Rodrigues W, Freitas DM, Muniz A, Oliveira P, Carvalho EM. Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology. 2007;69:813-818.

7. Oliveira P, de Castro NM, Carvalho EM. Urinary and sexual manifestations of patients infected by HTLV-I. Clinics (Sao Paulo). 2007;62:191-196.

8. Carneiro NJA, Bittencourt VG, de Oliveira C, Andrade R, Carvalho EM. The use of botulinum toxin type A in the treatment of HTLV-I associated overactive bladder refractory to conventional therapy. Rev Soc Bras Med Trop. 2014;47:528-532.

9. Castro NM, Freitas DM, Rodrigues W Jr, Oliveira P, Muniz A, Carvalho EM. Clinical efficacy of an anticholinergic agent in HAM/TSP patients with neurogenic bladder. Einstein. 2005;3:251-254.

10. Croda MG, Oliveira AC, Vergara MP, et al. Corticosteroid therapy in TSP/HAM patients: the results from a 10 years open cohort. J Neurol Sci. 2008;269:133-137.

11. Chapple CR, Kaplan SA, Mitcheson D, et al. Mirabegron 50 mg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12 weeks and 1 year. Int J Urol. 2014;21:960-967.

12. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European–Australian Phase 3 trial. Eur Urol. 2013;63:283-295.

13. Matsuo T, Miyata Y, Kakoki K, et al. The efficacy of mirabegron additional therapy for lower urinary tract symptoms after treatment with α1-adrenergic receptor blocker monotherapy: prospective analysis of elderly men. BMC Urol. 2016;16:45.

14. Okamura K, Nojiri Y, Osuga Y, Tange C. Psychometric analysis of the international prostate symptom score for female lower urinary tract symptoms. Urology. 2009;73:1199-1202.

15. Osame M. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In: Blattner WA, ed. Human Retrovirology: HTLV. New York: Raven Press. 1990:191-197.

16. Castro NM, Rodrigues W Jr, Freitas DM, Muniz A, Carvalho EM. Neurrogenic bladder associated with HTLV-I: two stages of a same disease. Urol Panam. 2005;17:17-19.

17. Castro NM, Freitas DM, Rodrigues W Jr, Muniz A, Oliveira P, Carvalho EM. Urodynamic features of the voiding dysfunction in HTLV-1 infected individuals. Int Braz J Urol. 2007;33:238-244.

18. Costa DT, Santos AL, Castro NM, Siqueira IC, Carvalho Filho EM, Glesby MJ. Neurological symptoms and signs in HTLV-1 patients with overactive bladder syndrome. Arq Neuropsiquiatr. 2012;70:252-256.

19. Vale DAD, Casseb J, de Oliveira ACP, Bussoleti Filho I, de Sousa SCOM, Ortega KL. Prevalence of Sjögren’s syndrome in Brazilian patients infected with human T-cell lymphotropic virus. J Oral Pathol Med. 2017;46:543-548.

20. Sanford M. OnabotulinumtoxinA (Botox®): a review of its use in the treatment of urinary incontinence in patients with multiple sclerosis or subcervical spinal cord injury. Drugs. 2014;74:1659-1672.

21. Komine S, Yoshida K, Yamashita H, Masaki Z. Voiding dysfunction in patients with human T-lymphotropic virus type-1-associated myelopathy (HAM). Paraplegia. 1989;27:217-221.

22. Imran M, Najmi AK, Tabrez S. Mirabegron for overactive bladder: a novel, first-in-class β3-agonist therapy. Urol J. 2013;10:935-940.

23. Chapple CR, Kaplan SA, Mitcheson D, et al. Randomized double-blind, active-controlled Phase 3 study to assess 12-month safety and efficacy of mirabegron, a β3-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63:296-305.

24. Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54:543-562.

25. Coler-Reilly AL, Yagishita N, Suzuki H, et al. Nation-wide epidemiological study of Japanese patients with rare viral myelopathy using novel registration system (HAM net). Orphanet J Rare Dis. 2016;11:69.

26. Nakamura H, Shimizu T, Takagi Y, et al. Reevaluation for clinical manifestations of HTLV-I-seropositive patients with Sjögren’s syndrome. BMC Musculoskelet Disord. 2015;16:335.

27. Martins FM, Casseb J, Penalva-de-Oliveira AC, de Paiva MF, Watanuki F, Ortega KL. Oral manifestations of human T-cell lymphotropic virus infection in adult patients from Brazil. Oral Dis. 2010;16:167-171.

28. Capo’ JP, Lucente V, Forero-Schwanhaeuser S, He W. Efficacy and tolerability of solifenacin in patients aged ≥65 years with overactive bladder: post-hoc analysis of 2 open-label studies. Postgrad Med. 2011;123:94-104.

29. Wagg A, Dale M, Tretter R, Stow B, Comption G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol. 2013;64:74-81.

How to cite this article: Matsuo T, Miyata Y, Nakamura T, Satoh K, Sakai H. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy. Lower Urinary Tract Symptoms. 2019;11:O65–O70. https://doi.org/10.1111/luts.12218